Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
10 recherche sur le mot-clé 'risperidone'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Risperidone versus aripiprazole fracture risk in children and adolescents with autism spectrum disorders / R. HOUGHTON in Autism Research, 14-8 (August 2021)
[article]
Titre : Risperidone versus aripiprazole fracture risk in children and adolescents with autism spectrum disorders Type de document : Texte imprimé et/ou numérique Auteurs : R. HOUGHTON, Auteur ; J. VAN DEN BERGH, Auteur ; K. LAW, Auteur ; Y. LIU, Auteur ; F. DE VRIES, Auteur Article en page(s) : p.1800-1814 Langues : Anglais (eng) Mots-clés : Adolescent Antipsychotic Agents/adverse effects Aripiprazole/adverse effects Autism Spectrum Disorder/complications/drug therapy/epidemiology Child Cohort Studies Female Fractures, Bone/drug therapy/epidemiology Humans Male Retrospective Studies Risperidone/adverse effects United States/epidemiology antipsychotics aripiprazole autism spectrum disorder fractures risperidone Index. décimale : PER Périodiques Résumé : Risperidone and aripiprazole, commonly used antipsychotics in children with autism spectrum disorder (ASD), have previously been associated with elevated fracture risk in other populations. The aim of this study was to evaluate and compare the risk of fracture among children with ASD using risperidone or aripiprazole. This was a retrospective, propensity-score matched cohort study, set between January 2013 and December 2018. We used the MarketScan Medicaid insurance data, which covers multiple states of the United States. We included ASD children aged 2-18?years, who were new users of aripiprazole or risperidone and with no prior history of antipsychotic use or fractures. The main exposure was the continued use of aripiprazole or risperidone. The incidence rates of any fracture during follow-up were evaluated, and the risk between aripiprazole and risperidone was compared via Cox-proportional hazard models. Results were stratified by age, sex, duration of exposure and fracture site. In total, 3312 patients (78% male; mean [SD] age 11.0 [3.7] years) were identified for each cohort. Over the full duration of follow-up, fracture incidence rates per 1000 patient-years were 23.2 for risperidone and 38.4 for aripiprazole (hazard ratio and 95% confidence interval: 0.60 [0.44-0.83]). Risks were similar between cohorts throughout the first 180?days on treatment, but significantly higher in the aripiprazole group thereafter. Extremity fractures drove most of the increased risk, with the biggest differences in lower leg and ankle fractures. Differences widened for children aged 10?years or younger (HR [95% CI]: 0.47 [0.30-0.74]). In conclusion, compared to aripiprazole, risperidone was associated with 40% lower risk of fracture. Further analysis on the mechanism and long-term bone health of antipsychotic-treated children with ASD is warranted. LAY SUMMARY: We compared the risk of bone fractures among 6624 children with autism spectrum disorder (ASD), half of whom used risperidone and half of whom used aripiprazole. Taking other factors into account, risks were similar between the two groups throughout the first 180?days on treatment, but significantly higher in the aripiprazole group thereafter. The biggest differences were in lower leg and ankle fractures. Overall, compared with aripiprazole, risperidone was associated with 40% lower risk of fracture. En ligne : http://dx.doi.org/10.1002/aur.2541 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=449
in Autism Research > 14-8 (August 2021) . - p.1800-1814[article] Risperidone versus aripiprazole fracture risk in children and adolescents with autism spectrum disorders [Texte imprimé et/ou numérique] / R. HOUGHTON, Auteur ; J. VAN DEN BERGH, Auteur ; K. LAW, Auteur ; Y. LIU, Auteur ; F. DE VRIES, Auteur . - p.1800-1814.
Langues : Anglais (eng)
in Autism Research > 14-8 (August 2021) . - p.1800-1814
Mots-clés : Adolescent Antipsychotic Agents/adverse effects Aripiprazole/adverse effects Autism Spectrum Disorder/complications/drug therapy/epidemiology Child Cohort Studies Female Fractures, Bone/drug therapy/epidemiology Humans Male Retrospective Studies Risperidone/adverse effects United States/epidemiology antipsychotics aripiprazole autism spectrum disorder fractures risperidone Index. décimale : PER Périodiques Résumé : Risperidone and aripiprazole, commonly used antipsychotics in children with autism spectrum disorder (ASD), have previously been associated with elevated fracture risk in other populations. The aim of this study was to evaluate and compare the risk of fracture among children with ASD using risperidone or aripiprazole. This was a retrospective, propensity-score matched cohort study, set between January 2013 and December 2018. We used the MarketScan Medicaid insurance data, which covers multiple states of the United States. We included ASD children aged 2-18?years, who were new users of aripiprazole or risperidone and with no prior history of antipsychotic use or fractures. The main exposure was the continued use of aripiprazole or risperidone. The incidence rates of any fracture during follow-up were evaluated, and the risk between aripiprazole and risperidone was compared via Cox-proportional hazard models. Results were stratified by age, sex, duration of exposure and fracture site. In total, 3312 patients (78% male; mean [SD] age 11.0 [3.7] years) were identified for each cohort. Over the full duration of follow-up, fracture incidence rates per 1000 patient-years were 23.2 for risperidone and 38.4 for aripiprazole (hazard ratio and 95% confidence interval: 0.60 [0.44-0.83]). Risks were similar between cohorts throughout the first 180?days on treatment, but significantly higher in the aripiprazole group thereafter. Extremity fractures drove most of the increased risk, with the biggest differences in lower leg and ankle fractures. Differences widened for children aged 10?years or younger (HR [95% CI]: 0.47 [0.30-0.74]). In conclusion, compared to aripiprazole, risperidone was associated with 40% lower risk of fracture. Further analysis on the mechanism and long-term bone health of antipsychotic-treated children with ASD is warranted. LAY SUMMARY: We compared the risk of bone fractures among 6624 children with autism spectrum disorder (ASD), half of whom used risperidone and half of whom used aripiprazole. Taking other factors into account, risks were similar between the two groups throughout the first 180?days on treatment, but significantly higher in the aripiprazole group thereafter. The biggest differences were in lower leg and ankle fractures. Overall, compared with aripiprazole, risperidone was associated with 40% lower risk of fracture. En ligne : http://dx.doi.org/10.1002/aur.2541 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=449 Risperidone and the 5-HT2A Receptor Antagonist M100907 Improve Probabilistic Reversal Learning in BTBR T?+?tf/J Mice / Dionisio A. AMODEO in Autism Research, 7-5 (October 2014)
[article]
Titre : Risperidone and the 5-HT2A Receptor Antagonist M100907 Improve Probabilistic Reversal Learning in BTBR T?+?tf/J Mice Type de document : Texte imprimé et/ou numérique Auteurs : Dionisio A. AMODEO, Auteur ; Joshua H. JONES, Auteur ; John A. SWEENEY, Auteur ; Michael E. RAGOZZINO, Auteur Article en page(s) : p.555-567 Langues : Anglais (eng) Mots-clés : autism cognitive flexibility BTBR reversal learning serotonin risperidone Index. décimale : PER Périodiques Résumé : Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impaired social interactions with restricted interests and repetitive behaviors (RRBs). RRBs can severely limit daily living and be particularly stressful to family members. To date, there are limited options for treating this feature in ASD. Risperidone, an atypical antipsychotic, is approved to treat irritability in ASD, but less is known about whether it is effective in treating “higher order” RRBs, for example cognitive inflexibility. Risperidone also has multiple receptor targets in which only a subset may be procognitive and others induce cognitive impairment. 5HT2A receptor blockade represents one promising and more targeted approach, as various preclinical studies have shown that 5HT2A receptor antagonists improve cognition. The present study investigated whether risperidone and/or M100907, a 5HT2A receptor antagonist, improved probabilistic reversal learning performance in the BTBR T?+?tf/J (BTBR) mouse model of autism. The effects of these treatments were also investigated in C57BL/6J (B6) mice as a comparison strain. Using a spatial reversal learning test with 80/20 probabilistic feedback, similar to one in which ASD individuals exhibit impairments, both risperidone (0.125?mg) and M100907 (0.01 and 0.1?mg) improved reversal learning in BTBR mice. Risperidone (0.125?mg) impaired reversal learning in B6 mice. Improvement in probabilistic reversal learning performance resulted from treatments enhancing the maintenance of the newly correct choice pattern. Because risperidone can lead to unwanted side effects, treatment with a specific 5HT2A receptor antagonist may improve cognitive flexibility in individuals with ASD while also minimizing unwanted side effects. Autism Res 2014, 7: 555–567. © 2014 International Society for Autism Research, Wiley Periodicals, Inc. En ligne : http://dx.doi.org/10.1002/aur.1395 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=241
in Autism Research > 7-5 (October 2014) . - p.555-567[article] Risperidone and the 5-HT2A Receptor Antagonist M100907 Improve Probabilistic Reversal Learning in BTBR T?+?tf/J Mice [Texte imprimé et/ou numérique] / Dionisio A. AMODEO, Auteur ; Joshua H. JONES, Auteur ; John A. SWEENEY, Auteur ; Michael E. RAGOZZINO, Auteur . - p.555-567.
Langues : Anglais (eng)
in Autism Research > 7-5 (October 2014) . - p.555-567
Mots-clés : autism cognitive flexibility BTBR reversal learning serotonin risperidone Index. décimale : PER Périodiques Résumé : Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impaired social interactions with restricted interests and repetitive behaviors (RRBs). RRBs can severely limit daily living and be particularly stressful to family members. To date, there are limited options for treating this feature in ASD. Risperidone, an atypical antipsychotic, is approved to treat irritability in ASD, but less is known about whether it is effective in treating “higher order” RRBs, for example cognitive inflexibility. Risperidone also has multiple receptor targets in which only a subset may be procognitive and others induce cognitive impairment. 5HT2A receptor blockade represents one promising and more targeted approach, as various preclinical studies have shown that 5HT2A receptor antagonists improve cognition. The present study investigated whether risperidone and/or M100907, a 5HT2A receptor antagonist, improved probabilistic reversal learning performance in the BTBR T?+?tf/J (BTBR) mouse model of autism. The effects of these treatments were also investigated in C57BL/6J (B6) mice as a comparison strain. Using a spatial reversal learning test with 80/20 probabilistic feedback, similar to one in which ASD individuals exhibit impairments, both risperidone (0.125?mg) and M100907 (0.01 and 0.1?mg) improved reversal learning in BTBR mice. Risperidone (0.125?mg) impaired reversal learning in B6 mice. Improvement in probabilistic reversal learning performance resulted from treatments enhancing the maintenance of the newly correct choice pattern. Because risperidone can lead to unwanted side effects, treatment with a specific 5HT2A receptor antagonist may improve cognitive flexibility in individuals with ASD while also minimizing unwanted side effects. Autism Res 2014, 7: 555–567. © 2014 International Society for Autism Research, Wiley Periodicals, Inc. En ligne : http://dx.doi.org/10.1002/aur.1395 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=241 Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study / Justine M. KENT in Journal of Autism and Developmental Disorders, 43-8 (August 2013)
[article]
Titre : Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study Type de document : Texte imprimé et/ou numérique Auteurs : Justine M. KENT, Auteur ; Stuart KUSHNER, Auteur ; Xiaoping NING, Auteur ; Keith KARCHER, Auteur ; Seth NESS, Auteur ; Michael G. AMAN, Auteur ; Jaskaran SINGH, Auteur ; David HOUGH, Auteur Article en page(s) : p.1773-1783 Langues : Anglais (eng) Mots-clés : Autistic disorder Double-blind Placebo-controlled Risperidone Index. décimale : PER Périodiques Résumé : Efficacy and safety of 2 risperidone doses were evaluated in children and adolescents with autism. Patients (N = 96; 5–17 years), received risperidone (low-dose: 0.125 mg/day [20 to 45 kg], 0.175 mg/day [45 kg] or high-dose: 1.25 mg/day [20 to 45 kg], 1.75 mg/day [45 kg]) or placebo. Mean baseline (range 27–29) to endpoint change in Aberrant Behavior Checklist-Irritability (primary endpoint) was significantly greater in the high-dose—(?12.4 [6.5]; p 0.001), but not low-dose (?7.4 [8.1]; p = 0.164) group, versus placebo (?3.5 [10.7]). Clinical Global Impressions-Severity and Children’s Yale-Brown Obsessive Compulsive Scale scores improved significantly only in the high-dose group, consistent with ABC-I results. Somnolence, sedation and increased appetite occurred more frequently in high-versus low-dose groups. Overall, increased appetite occurred most frequently. En ligne : http://dx.doi.org/10.1007/s10803-012-1723-5 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=205
in Journal of Autism and Developmental Disorders > 43-8 (August 2013) . - p.1773-1783[article] Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study [Texte imprimé et/ou numérique] / Justine M. KENT, Auteur ; Stuart KUSHNER, Auteur ; Xiaoping NING, Auteur ; Keith KARCHER, Auteur ; Seth NESS, Auteur ; Michael G. AMAN, Auteur ; Jaskaran SINGH, Auteur ; David HOUGH, Auteur . - p.1773-1783.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 43-8 (August 2013) . - p.1773-1783
Mots-clés : Autistic disorder Double-blind Placebo-controlled Risperidone Index. décimale : PER Périodiques Résumé : Efficacy and safety of 2 risperidone doses were evaluated in children and adolescents with autism. Patients (N = 96; 5–17 years), received risperidone (low-dose: 0.125 mg/day [20 to 45 kg], 0.175 mg/day [45 kg] or high-dose: 1.25 mg/day [20 to 45 kg], 1.75 mg/day [45 kg]) or placebo. Mean baseline (range 27–29) to endpoint change in Aberrant Behavior Checklist-Irritability (primary endpoint) was significantly greater in the high-dose—(?12.4 [6.5]; p 0.001), but not low-dose (?7.4 [8.1]; p = 0.164) group, versus placebo (?3.5 [10.7]). Clinical Global Impressions-Severity and Children’s Yale-Brown Obsessive Compulsive Scale scores improved significantly only in the high-dose group, consistent with ABC-I results. Somnolence, sedation and increased appetite occurred more frequently in high-versus low-dose groups. Overall, increased appetite occurred most frequently. En ligne : http://dx.doi.org/10.1007/s10803-012-1723-5 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=205 Risperidone plasma concentrations are associated with hyperprolactinemia in autism spectrum disorder children: The impact of CYP2D6 polymorphisms / Monpat CHAMNANPHON in Research in Autism Spectrum Disorders, 96 (August 2022)
[article]
Titre : Risperidone plasma concentrations are associated with hyperprolactinemia in autism spectrum disorder children: The impact of CYP2D6 polymorphisms Type de document : Texte imprimé et/ou numérique Auteurs : Monpat CHAMNANPHON, Auteur ; Natchaya VANWONG, Auteur ; Santirhat PROMMAS, Auteur ; Napatrupron KOOMDEE, Auteur ; Rattanaporn SUKPRASONG, Auteur ; Jiratha RACHANAKUL, Auteur ; Nutthan NUNTHARADTHANAPHONG, Auteur ; Yaowaluck HONGKAEW, Auteur ; Shobana JOHN, Auteur ; Nattawat NGAMSAMUT, Auteur ; Nopphadol NUNTAMOOL, Auteur ; Penkhae LIMSILA, Auteur ; Chonlaphat SUKASEM, Auteur Article en page(s) : 102002 Langues : Anglais (eng) Mots-clés : genotyping Prolactin ASD Risperidone Allele-specific primer extension Luminex xTAG Chemiluminescence immunoassay Index. décimale : PER Périodiques Résumé : Background Risperidone causes hyperprolactinemia by blocking D2 receptors on lactotrophs anterior pituitary, which prevents prolactin secretion inhibition. Risperidone is converted to 9-hydroxyrisperidone by the CYP2D6 enzyme. Polymorphisms in CYP2D6 may affect serum prolactin and could be a predictor of hyperprolactinemia. The goal of this study was to see if there was an association between CYP2D6 variants, risperidone dose, clinical data and serum prolactin levels in Thai children and adolescents with autism spectrum disorder (ASD). Method In 107 Thai ASD patients on risperidone, allele-specific primer extension and multiplex PCR platforms were used to genotype the CYP2D6 gene. The chemiluminescence immunoassay (CLIA) technique was used to measure fasting serum prolactin levels. Results The median serum prolactin level was 16.25?ng/mL (IQR; 10.43-22.18), and patients with CYP2D6*1/*5 (6.54%) had substantially lower prolactin levels than those with CYP2D6*1/*1 [median; 11.2?ng/mL (IQR; 3.95-21.10) vs. 21.3 (IQR; 14.43-32.18), p=0.032]. CYP2D6*1/*10, *10/*10, and *10/*41 produced less prolactin than *1/*1 (wild type). Furthermore, gender and risperidone dose were associated with significantly different prolactin levels with p-value 0.02 and 0.006, respectively. Multivariate analysis showed a significant association of serum prolactin level with body mass index and risperidone dose (p<0.05). Conclusions Our study showed that CYP2D6 carriers of absent and decreased functional alleles had lower serum prolactin levels in Thai ASD patients treated with risperidone treatment; this is important to clinicians, indicating that they should consider about CYP2D6 genotyping before beginning risperidone in ASD patients. CYP2D6 genotypes might be a predictor for levels of prolactin in clinical treatment. En ligne : https://doi.org/10.1016/j.rasd.2022.102002 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=480
in Research in Autism Spectrum Disorders > 96 (August 2022) . - 102002[article] Risperidone plasma concentrations are associated with hyperprolactinemia in autism spectrum disorder children: The impact of CYP2D6 polymorphisms [Texte imprimé et/ou numérique] / Monpat CHAMNANPHON, Auteur ; Natchaya VANWONG, Auteur ; Santirhat PROMMAS, Auteur ; Napatrupron KOOMDEE, Auteur ; Rattanaporn SUKPRASONG, Auteur ; Jiratha RACHANAKUL, Auteur ; Nutthan NUNTHARADTHANAPHONG, Auteur ; Yaowaluck HONGKAEW, Auteur ; Shobana JOHN, Auteur ; Nattawat NGAMSAMUT, Auteur ; Nopphadol NUNTAMOOL, Auteur ; Penkhae LIMSILA, Auteur ; Chonlaphat SUKASEM, Auteur . - 102002.
Langues : Anglais (eng)
in Research in Autism Spectrum Disorders > 96 (August 2022) . - 102002
Mots-clés : genotyping Prolactin ASD Risperidone Allele-specific primer extension Luminex xTAG Chemiluminescence immunoassay Index. décimale : PER Périodiques Résumé : Background Risperidone causes hyperprolactinemia by blocking D2 receptors on lactotrophs anterior pituitary, which prevents prolactin secretion inhibition. Risperidone is converted to 9-hydroxyrisperidone by the CYP2D6 enzyme. Polymorphisms in CYP2D6 may affect serum prolactin and could be a predictor of hyperprolactinemia. The goal of this study was to see if there was an association between CYP2D6 variants, risperidone dose, clinical data and serum prolactin levels in Thai children and adolescents with autism spectrum disorder (ASD). Method In 107 Thai ASD patients on risperidone, allele-specific primer extension and multiplex PCR platforms were used to genotype the CYP2D6 gene. The chemiluminescence immunoassay (CLIA) technique was used to measure fasting serum prolactin levels. Results The median serum prolactin level was 16.25?ng/mL (IQR; 10.43-22.18), and patients with CYP2D6*1/*5 (6.54%) had substantially lower prolactin levels than those with CYP2D6*1/*1 [median; 11.2?ng/mL (IQR; 3.95-21.10) vs. 21.3 (IQR; 14.43-32.18), p=0.032]. CYP2D6*1/*10, *10/*10, and *10/*41 produced less prolactin than *1/*1 (wild type). Furthermore, gender and risperidone dose were associated with significantly different prolactin levels with p-value 0.02 and 0.006, respectively. Multivariate analysis showed a significant association of serum prolactin level with body mass index and risperidone dose (p<0.05). Conclusions Our study showed that CYP2D6 carriers of absent and decreased functional alleles had lower serum prolactin levels in Thai ASD patients treated with risperidone treatment; this is important to clinicians, indicating that they should consider about CYP2D6 genotyping before beginning risperidone in ASD patients. CYP2D6 genotypes might be a predictor for levels of prolactin in clinical treatment. En ligne : https://doi.org/10.1016/j.rasd.2022.102002 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=480 Predictors and Moderators of Parent Training Efficacy in a Sample of Children with Autism Spectrum Disorders and Serious Behavioral Problems / Cristan A. FARMER in Journal of Autism and Developmental Disorders, 42-6 (June 2012)
[article]
Titre : Predictors and Moderators of Parent Training Efficacy in a Sample of Children with Autism Spectrum Disorders and Serious Behavioral Problems Type de document : Texte imprimé et/ou numérique Auteurs : Cristan A. FARMER, Auteur ; Luc LECAVALIER, Auteur ; Sunkyung YU, Auteur ; L. Eugene ARNOLD, Auteur ; Christopher J. MCDOUGLE, Auteur ; Lawrence SCAHILL, Auteur ; Benjamin L. HANDEN, Auteur ; Cynthia JOHNSON, Auteur ; Kimberly A. STIGLER, Auteur ; Karen E. BEARSS, Auteur ; Naomi SWIEZY, Auteur ; Michael G. AMAN, Auteur Année de publication : 2012 Article en page(s) : p.1037-1044 Langues : Anglais (eng) Mots-clés : Parent training Pervasive developmental disorder Autism Risperidone Predictor Moderator Index. décimale : PER Périodiques Résumé : The Research Units on Pediatric Psychopharmacology—Autism Network reported additional benefit when adding parent training (PT) to antipsychotic medication in children with autism spectrum disorders and serious behavior problems. The intent-to-treat analyses were rerun with putative predictors and moderators. The Home Situations Questionnaire (HSQ) and the Hyperactivity/Noncompliance subscale of the Aberrant Behavior Checklist were used as outcome measures. Candidate predictors and moderators included 21 demographics and baseline measures of behavior. Higher baseline HSQ scores predicted greater improvement on the HSQ regardless of treatment assignment, but no other predictors of outcome were observed. None of the variables measured in this study moderated response to PT. Antipsychotic medication plus PT appears to be equally effective for children with a wide range of demographic and behavioral characteristics. En ligne : http://dx.doi.org/10.1007/s10803-011-1338-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=156
in Journal of Autism and Developmental Disorders > 42-6 (June 2012) . - p.1037-1044[article] Predictors and Moderators of Parent Training Efficacy in a Sample of Children with Autism Spectrum Disorders and Serious Behavioral Problems [Texte imprimé et/ou numérique] / Cristan A. FARMER, Auteur ; Luc LECAVALIER, Auteur ; Sunkyung YU, Auteur ; L. Eugene ARNOLD, Auteur ; Christopher J. MCDOUGLE, Auteur ; Lawrence SCAHILL, Auteur ; Benjamin L. HANDEN, Auteur ; Cynthia JOHNSON, Auteur ; Kimberly A. STIGLER, Auteur ; Karen E. BEARSS, Auteur ; Naomi SWIEZY, Auteur ; Michael G. AMAN, Auteur . - 2012 . - p.1037-1044.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 42-6 (June 2012) . - p.1037-1044
Mots-clés : Parent training Pervasive developmental disorder Autism Risperidone Predictor Moderator Index. décimale : PER Périodiques Résumé : The Research Units on Pediatric Psychopharmacology—Autism Network reported additional benefit when adding parent training (PT) to antipsychotic medication in children with autism spectrum disorders and serious behavior problems. The intent-to-treat analyses were rerun with putative predictors and moderators. The Home Situations Questionnaire (HSQ) and the Hyperactivity/Noncompliance subscale of the Aberrant Behavior Checklist were used as outcome measures. Candidate predictors and moderators included 21 demographics and baseline measures of behavior. Higher baseline HSQ scores predicted greater improvement on the HSQ regardless of treatment assignment, but no other predictors of outcome were observed. None of the variables measured in this study moderated response to PT. Antipsychotic medication plus PT appears to be equally effective for children with a wide range of demographic and behavioral characteristics. En ligne : http://dx.doi.org/10.1007/s10803-011-1338-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=156 Olanzapine, risperidone, and aripiprazole use in children and adolescents with Autism Spectrum Disorders / Selma TURAL HESAPCIOGLU in Research in Autism Spectrum Disorders, 72 (April 2020)
PermalinkBone Mass in Boys with Autism Spectrum Disorder / Chadi A. CALARGE in Journal of Autism and Developmental Disorders, 47-6 (June 2017)
PermalinkBrief Report: Social Disability in Autism Spectrum Disorder: Results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Trials / Lawrence SCAHILL in Journal of Autism and Developmental Disorders, 43-3 (March 2013)
PermalinkSensitivity of the modified Children’s Yale–Brown Obsessive Compulsive Scale to detect change: Results from two multi-site trials / Lawrence SCAHILL in Autism, 20-2 (February 2016)
PermalinkOverweight and obese status in children with autism spectrum disorder and disruptive behavior / K. K. CRIADO in Autism, 22-4 (May 2018)
Permalink